Other Mutations: ESO

NCT04939701: Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants

NCT04939701
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: ESO
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have tumors that are NY-ESO-1+; Breast cancer patients are only eligible for the dose escalation phase
Exclusions: Patients who have received prior checkpoint inhibitor therapy (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab); Patients with active untreated brain metastasis or leptomeningeal disease – see trial for details
https://ClinicalTrials.gov/show/NCT04939701

NCT04878484: Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors

NCT04878484
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: HLA+, ESO
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have tumors that are HLA-A*0201 positive & NY-ESO-1 positive
Exclusions: Patients with untreated or symptomatic brain metastasis
https://ClinicalTrials.gov/show/NCT04878484

Up ↑